News & Updates
Filter by Specialty:
Stage IIIA/B NSCLC: Perioperative nivolumab plus chemo improves pCR, survival vs neoadjuvant chemo
15 Sep 2023
bySarah Cheung
Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.
Stage IIIA/B NSCLC: Perioperative nivolumab plus chemo improves pCR, survival vs neoadjuvant chemo
15 Sep 2023Is it safe to take olmesartan in combination therapy for advanced hypertension?
14 Sep 2023
byStephen Padilla
Use of olmesartan in combination practice is safe and results in similar cardiovascular composite outcomes, including myocardial infarction (MI), when compared with active comparators in hypertensive patients who need more than two antihypertensive medications, reports a study.